GSK PLC GSK shares inched down 0.34% to £13.30 Friday, on what proved to be an all-around grim trading session for the stock ...

Nine months out from landing $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

GSK PLC GSK shares rose 2.90% to £13.83 Monday, on what proved to be an all-around great trading session for the stock market ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK has made the decision to withdraw Jesduvroq (daprodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, from the US market.

As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.